Literature DB >> 12056962

Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.

Hensin Tsao1, Peri Millman, Gerald P Linette, F Stephen Hodi, Arthur J Sober, Mark A Goldberg, Frank G Haluska.   

Abstract

BACKGROUND: Reports of vitiligo associated with metastases and rare cases of spontaneous regression of disease have fueled enthusiasm for immunologic approaches to the treatment of advanced melanoma. More recent strategies have focused on using antigen-presenting dendritic cells as vaccines. OBSERVATIONS: We observed 3 cases of leukoderma associated with a novel adenovirus-mediated gp100/MART-1-transduced dendritic cell (MART indicates melanoma antigen recognized by T cells). All 3 patients had advanced metastatic melanoma. Despite the development of this leukodermic response, all patients experienced disease progression while under treatment.
CONCLUSION: We provide the initial evidence for effective induction of a leukodermic response with a gp100/MART-1-transduced dendritic cell vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056962     DOI: 10.1001/archderm.138.6.799

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

Review 1.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

Review 2.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

3.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

4.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

Review 5.  Immune-related cutaneous adverse events due to checkpoint inhibitors.

Authors:  Evelyn Wang; Lukas Kraehenbuehl; Kwami Ketosugbo; Jeffrey A Kern; Mario E Lacouture; Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2021-02-17       Impact factor: 6.248

Review 6.  Gene therapy for cancer: present status and future perspective.

Authors:  Magid H Amer
Journal:  Mol Cell Ther       Date:  2014-09-10

7.  Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.

Authors:  Hadas Prag Naveh; Lazar Vujanovic; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2013-11-18       Impact factor: 13.751

Review 8.  The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.